NCT02172560 - A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler | Biotech Hunter

Enrollment

441

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

January 31, 2008

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Tiotropium

Trial Locations (19)

Boehringer Ingelheim Investigational Site 61501, Garran

Boehringer Ingelheim Investigational Site 61403, Clayton

Boehringer Ingelheim Investigational Site 61502, Adelaide

Boehringer Ingelheim Investigational Site 61401, Woodsville South

Boehringer Ingelheim Investigational Site 61402, Frankston

Boehringer Ingelheim Investigational Site 61503, Nedlands

Boehringer Ingelheim Investigational Site 61405, Perth

Boehringer Ingelheim Investigational Site 61505, Hamilton

Boehringer Ingelheim Investigational Site 61504, Otahuhu

Boehringer Ingelheim Investigational Site 44402, Birmingham

Boehringer Ingelheim Investigational Site 44409, Bristol

Boehringer Ingelheim Investigational Site 44502, Devon

Boehringer Ingelheim Investigational Site 44504, Hull

Boehringer Ingelheim Investigational Site 44507, Isleworth

Boehringer Ingelheim Investigational Site 44506, Manchester

Boehringer Ingelheim Investigational Site 44403, Nottingham

Boehringer Ingelheim Investigational Site 44405, Swansea

Boehringer Ingelheim Investigational Site 44404, Torquay

Boehringer Ingelheim Investigational Site 44505, Torquay